.Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AK10_VilanterolAndFluticasone.VilanterolAndFluticasone .Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AK10_VilanterolAndFluticasone.VilanterolAndFluticasone| name: | VilanterolAndFluticasoneFuroate |
| ATC code: | R03AK10 | route: | inhalation |
| n-compartments | 2 |
Vilanterol and fluticasone furoate is a combination inhaled medication used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Vilanterol is a long-acting beta2-adrenergic agonist (LABA), while fluticasone furoate is an inhaled corticosteroid. The drug is approved and regularly used in clinical practice for long-term management of airway obstruction.
Pharmacokinetic parameters derived from published studies in healthy adult subjects for inhaled administration of vilanterol 25 mcg and fluticasone furoate 100 mcg once daily.
Siederer, S, et al., & Yang, S (2016). Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease. European journal of drug metabolism and pharmacokinetics 41(6) 743–758. DOI:10.1007/s13318-015-0303-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26474864
Allen, A, et al., & Yang, S (2016). Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in adult and adolescent patients with asthma. International journal of clinical pharmacology and therapeutics 54(4) 269–281. DOI:10.5414/CP202438 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26902504
Yang, S, et al., & Peachey, G (2021). Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN). Clinical pharmacokinetics 60(7) 887–896. DOI:10.1007/s40262-021-00988-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33598874